

Embedding Multimodal Rehabilitation Within Routine Cancer Care in Sheffield—The Active Together Service Evaluation Protocol

MYERS, Anna <<http://orcid.org/0000-0001-6432-8628>>, HUMPHREYS, Liam <<http://orcid.org/0000-0002-9279-1019>>, THELWELL, Michael <<http://orcid.org/0000-0003-0145-0452>>, PICKERING, Katie <<http://orcid.org/0000-0003-1534-1775>>, FRITH, Gabriella <<http://orcid.org/0000-0002-2327-2602>>, PHILLIPS, Gail <<http://orcid.org/0009-0004-1120-0419>>, KEEN, Carol <<http://orcid.org/0000-0001-7803-1235>>, COPELAND, Robert <<http://orcid.org/0000-0002-4147-5876>> and __, __

Available from Sheffield Hallam University Research Archive (SHURA) at:

<https://shura.shu.ac.uk/34116/>

This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it.

Published version

MYERS, Anna, HUMPHREYS, Liam, THELWELL, Michael, PICKERING, Katie, FRITH, Gabriella, PHILLIPS, Gail, KEEN, Carol, COPELAND, Robert and __, __ (2024). Embedding Multimodal Rehabilitation Within Routine Cancer Care in Sheffield—The Active Together Service Evaluation Protocol. *Journal of Physical Activity and Health*, 1-12.

Copyright and re-use policy

See <http://shura.shu.ac.uk/information.html>

1 **Embedding multimodal rehabilitation within routine cancer care in Sheffield – The Active Together**
2 **service evaluation protocol**

3 **ABSTRACT**

4 **Background:** Approximately three million people in the United Kingdom (UK) are currently living with
5 or beyond cancer. People undergoing treatment for cancer are at risk of complications following
6 treatment. Increasing evidence supports the role of rehabilitation (including prehabilitation) for
7 enhancing psychological and physical wellbeing in cancer patients and improving outcomes. Active
8 Together is an evidence-based, multimodal rehabilitation service for patients with cancer, providing
9 support to help patients prepare for and recover from treatment. This paper presents the evaluation
10 protocol for the Active Together service, aiming to determine its impact on patient-reported outcomes
11 and clinical endpoints, as well as understand processes and mechanisms that influence its delivery and
12 outcomes.

13 **Methods:** This evaluation comprises an outcome and process evaluation, with service implementation
14 data integrated into the analysis of outcome measures. The outcome evaluation will assess changes
15 in outcomes of patients that attend the service, and compare healthcare resource use against
16 historical data. The process evaluation will use performance indicators, semi-structured interviews
17 and focus groups to explore mechanisms of action and contextual factors influencing delivery and
18 outcomes. Integrating psychological change mechanisms with outcome data might help to clarify
19 complex causal pathways within the service.

20 **Conclusions:** Evidence to support the role of multimodal rehabilitation before, during and after cancer
21 treatment is increasing. The translation of that evidence into practice is less advanced. Findings from
22 this evaluation will contribute to our understanding of the real-world impact of cancer rehabilitation
23 and strengthen the case for widespread adoption of rehabilitation into routine care for people with
24 cancer.

25 BACKGROUND

26 Approximately three million people in the UK are currently living with or beyond cancer and this is
27 predicted to rise to four million by 2030¹. People undergoing treatment for cancer may experience, or
28 be at risk of, adverse effects, particularly those who do not possess sufficient physiological resilience
29 to tolerate treatment². For example, most patients with cancer undergo surgical procedures and 30%
30 of patients develop post-operative complications that delay discharge from hospital³. Complications
31 during and following treatment inflate costs (longer hospital length of stay (LOS), more interventions
32 and increased readmissions) and worsen patient experience⁴. Furthermore, surgical outcomes vary
33 according to the operative procedure carried out and patient fitness⁵. This is unsurprising given the
34 physiological and psychological strains resulting from cancer treatments⁶, with high-risk groups (e.g.,
35 frail and unfit) particularly affected by treatment⁴. Cancer patients are also at risk of malnutrition prior
36 to surgery, and this is related to physical and psychological outcomes⁷. Adverse effects associated with
37 cancer and its treatment include cancer-related fatigue, anxiety, depression, peripheral neuropathy,
38 weight changes, osteoporosis, lymphoedema, urinary and bowel problems, night sweats, hot flushes
39 and difficulty with memory and concentration⁸. It is estimated that 78% of cancer survivors
40 experienced one or more of these side-effects in the last 12 months, while 71% report at least one of
41 these more than ten years after treatment⁹.

42 Cancer is increasingly viewed as a long-term condition^{10,11}. Advances in technology, improved cancer
43 treatments, screening programmes, improved diagnostics and input from multidisciplinary teams
44 have led to an increase in the number of people living for longer with cancer. However, not everyone
45 is living well – one in four of those living with cancer (~500,000 people in the UK) face poor health and
46 disability after treatment¹² and one in five may have unmet need¹³. Inequalities in treatment
47 outcomes increase strain on the healthcare system and negatively impact the quality of life of those
48 most in need, with individuals from the most deprived areas more likely to suffer from diseases linked
49 to unhealthy lifestyle behaviours, such as cardiovascular disease, obesity and cancer¹⁴. Tackling these
50 inequalities by improving the quality of and access to support for people with a cancer diagnosis,

51 especially those living in disadvantaged communities who do not typically access services, must be a
52 health service priority¹⁵.

53 Cancer rehabilitation (including prehabilitation) is a multimodal, multi-disciplinary approach that aims
54 to improve outcomes and patient experiences of treatment, through the provision of physical activity,
55 nutrition, and psychological support. Evidence in support of the role of multimodal interventions to
56 improve psychological and physical wellbeing in cancer patients and reduce the negative impact of
57 cancer related side-effects at all stages of cancer treatment is growing rapidly¹⁶⁻¹⁹. Support throughout
58 the cancer treatment pathway has been shown to improve several modifiable risk factors (e.g., cardio-
59 respiratory fitness, psychological wellbeing, nutritional status) before treatment, so that people are
60 fitter^{7,20}, can tolerate acute treatment more effectively and recover well after treatment²¹. This
61 promotes earlier discharge²² and reduces treatment-related adverse effects²³. There is also an
62 opportunity to improve psycho-social support and patient experience, which is particularly important
63 for patients who are already vulnerable and have pre-existing mental health difficulties.

64 Observational studies have linked insufficient physical activity²⁴ and poor nutrition²⁵ with disease-
65 related outcomes such as cancer recurrence risk, death from cancer, and overall mortality. There is
66 increasing evidence that physical activity, psychological state and nutrition are related to prognosis
67 and survival after cancer²⁶. Evidence now suggests that regular exercise before, during and after
68 treatment decreases the severity of treatment-related adverse side effects and is associated with
69 reduced risk of cancer recurrence, mortality and comorbid conditions^{23,27,28}. Being more physically
70 active after a cancer diagnosis is associated with a 21-35% lower risk of cancer recurrence, a 28-44%
71 reduced risk of cancer-specific mortality and a 25-48% reduced risk of all-cause mortality for some
72 cancers²³. However, it is important to note that the recurrence and mortality evidence is limited due
73 to the epidemiological nature of the literature, the few experimental trials that do assess recurrence
74 and mortality are not statistically powered to detect an effect in those outcomes, there are
75 inconsistencies in defining endpoints and the tools used to assess physical activity are often open to
76 measurement error. There are likely broader impacts of cancer rehabilitation on the health system

77 such as optimising treatment, reducing hospital length of stay, reducing complications during and after
78 treatment, which will have financial and broader societal benefits. The aim of this paper is to describe
79 the mixed-methods evaluation of a multimodal rehabilitation service for people living with cancer –
80 the Active Together service.

81 **METHODS**

82 **The Active Together service**

83 The Advanced Wellbeing Research Centre (AWRC) at Sheffield Hallam University (SHU), in partnership
84 with Yorkshire Cancer Research (YCR) and Sheffield Teaching Hospitals National Health Service (NHS)
85 Foundation Trust (STH) have implemented an evidence-based multimodal rehabilitation pathway for
86 people living with cancer²⁹. During the first three years, the Active Together service will focus on
87 providing support for patients with lung, colorectal or upper gastrointestinal cancer, under the care
88 of STH, who are being treated with curative intent. Since February 2022, patients over the age of 18
89 years who receive treatment in Sheffield are referred to Active Together for personalised physical
90 activity, dietetic and psychological support based on a comprehensive needs assessment. Support
91 spans the rehabilitation continuum, from preventive rehabilitation (prehabilitation) following
92 diagnosis, maintenance rehabilitation during treatment, through to restorative and supportive
93 rehabilitation after treatment. The service is being delivered and supported by a multidisciplinary
94 team of staff including physiotherapists, dietitians, psychologists, specialist exercise professionals,
95 administrative staff, and academics. For key challenges, insights and learnings from the first 12 months
96 of the service, see the recent paper by Keen et al. ³⁰.

97 The purpose of the Active Together service is to embed multimodal rehabilitation support, at all stages
98 of the cancer treatment journey, within existing clinical pathways for people affected by cancer who
99 are treated in Sheffield. Beyond the initial three years, the ambition is to expand the service delivery
100 to include patients with other forms of cancer, and scale to other NHS trusts across Yorkshire and
101 beyond. The service aims to improve clinical, and patient reported outcomes such as functional

102 capacity, psychological wellbeing, treatment-related side effects, tolerance to treatments, post-
103 operative complications, and survival rates. For further information about the design of the Active
104 Together service, see Humphreys et al.²⁹. The level of physical activity, nutritional or psychological
105 support offered to patients will be determined on an individual basis according to the results of an
106 initial needs assessment. For the exercise prescription, the aim is to achieve 30 minutes of moderate
107 intensity aerobic exercise three times per week and two sessions of resistance exercise twice per
108 week. Each patient's starting point will depend on their current fitness and cancer/treatment related
109 side effects when they enter the service.

110

111 **The Active Together service evaluation**

112 This protocol is reported according to the Transparent Reporting of Evaluations with Non-randomized
113 Designs (TREND) guidelines³¹.

114 The service evaluation protocol has been reviewed by the Health Research Authority (HRA) who
115 concluded that formal NHS ethical approval was not required because no new or untested treatment
116 is being offered and there is no experimentation being conducted with patients. The service evaluation
117 has been approved by the Clinical Effectiveness Unit (CEU) at Sheffield Teaching Hospitals NHS
118 Foundation Trust (Ref 11115 - 19/5/2022). Informed consent for anonymised data to be used in the
119 service evaluation will be obtained from all patients prior to attending the service or during their initial
120 assessment. Evaluation data will be processed in accordance with the 2018 data protection act.

121 The purpose of the evaluation is to determine the impact of a multimodal rehabilitation (including
122 prehabilitation) service on patient outcomes, while also exploring service implementation,
123 mechanisms of action and contextual factors that influence delivery and outcomes. Data relating to
124 the implementation of the Active Together service will be integrated into the analysis of outcome
125 effectiveness measures using a mixed-methods design, aligned to the latest guidance on developing

126 and evaluating complex interventions³². In addition, data on intermediate processes identified in the
127 process evaluation might inform the inclusion of new outcome measures in future.

128

129 **Outcome evaluation design**

130 The primary aim of the outcome evaluation is to determine the impact of the Active Together service
131 on physical outcomes, patient-reported outcomes and clinical endpoints, as well as determine
132 benefits to the wider health system.

133 The outcome evaluation comprises both a single group, longitudinal design to determine the impact
134 of the Active Together service on measured outcomes (physical and patient-reported) throughout the
135 rehabilitation pathway, as well as a between group design (Active Together patients compared to non-
136 Active Together patients) using hospital records data to assess the impact on secondary healthcare
137 resource use and clinical endpoints. Both health resource usage and clinical endpoints data will be
138 made available through a data sharing agreement with STH. There will be three overall patient groups
139 to be compared with regard to hospital data: 1) patients that accept referral and attend the Active
140 Together service, 2) patients that decline referral and do not attend the Active Together service, and
141 3) patients who received treatment for cancer between March 2017 and January 2022, prior to the
142 launch of the Active Together service. These data will enable a comparison between patients that have
143 received rehabilitation from the Active Together service and those who received standard care
144 without rehabilitation.

145 Throughout the delivery of the Active Together service, patient outcomes will be measured at key
146 time-points (Figure 1) and recorded digitally in an anonymised database. This dataset, in combination
147 with health resource usage and clinical endpoint data will enable a pragmatic evaluation of the Active
148 Together service.

149 ***Data collection timepoints***

150 Patients will have outcome measures taken at an initial assessment at the AWRC (T1). The outcome
151 measures collected at this initial assessment determine the frequency and intensity of support
152 patients receive during the prehabilitation phase of the service, and provide a baseline for their
153 physical, psychological, and nutritional state for the purposes of the evaluation. Outcome measures
154 will be collected from patients at the end/beginning of each phase of the service pathway: post-
155 prehabilitation (pre-treatment) (T2); post-maintenance rehabilitation (post-treatment) (T3), post-
156 restorative rehabilitation (T4); post-supportive rehabilitation (T5) (Figure 1). In addition, patient
157 reported outcomes, as well as health resource usage and clinical outcomes data (length of stay,
158 readmission and 1-year survival) extracted from electronic patient records will be assessed at 12-
159 months following treatment (T6).

160 **FIGURE 1 HERE**

161
162 Due to the complexity and individualised nature of cancer and its treatment, not all patients will
163 proceed through the service pathway or these assessment points linearly. Instead, their service
164 pathway will depend on the type of cancer treatment they receive, as demonstrated in Figure 2. In
165 general, patients will be reassessed each time something changes in their treatment pathway.

166 **FIGURE 2 HERE**

167 The outcome measures that will be collected at each time point during the Active Together service
168 are shown in Table 1 and described in more detail below.

169 **TABLE 1 HERE**

170 **Outcome measures**

171 Outcome data will be collected by service delivery staff via service delivery records, electronic patient
172 records, questionnaires and physical measurement procedures. Training regarding data collection
173 methods for service delivery staff will be provided to maximise consistency and reliability. Hospital
174 data will be obtained from STH under a data sharing agreement. Primary and secondary outcomes are
175 described below.

176 Primary outcomes

177 **Aerobic capacity:** the 6-minute walk test (6MWT) will be used to provide a proxy of patients' aerobic
178 capacity. The 6MWT is a valid and reliable measure to estimate aerobic capacity in people with cancer
179 ³³. Aerobic capacity was chosen as the primary outcome for several reasons; the 6MWT is widely used
180 in the prehabilitation literature and therefore data can be compared and contrasted with other
181 research and service evaluation; it is a prognostic factor for survival in some cancers³⁴; it is associated
182 with postoperative complication and length of stay³⁵; and physical performance has been linked to
183 survival and treatment-related complications in older adults with cancer^{36,37}.

184 **Quality of life:** will be assessed using the European Quality of Life Five Dimensions questionnaire (EQ-
185 5D-5L) which has five domains focusing on mobility, self-care, usual activities, pain/discomfort and
186 anxiety/depression, with one question per domain³⁸. An additional visual analogue scale (VAS)
187 question asks individuals to rate their current overall health on a scale ranging from 0 to 100.

188 Secondary outcomes

189 **Lower limb strength and endurance:** will be assessed using the 30 and 60-second sit-to-stand test.
190 Patients will be encouraged to complete as many full sit-to-stand motions as possible within 60
191 seconds (the number of repetitions will also be recorded at 30-seconds)³⁹. If a patient is unable to
192 attend a face-to-face assessment (e.g., during isolation before chemotherapy/surgery) they will
193 complete the 60-seconds sit-to-stand at home; the number of repetitions completed in the full 60
194 seconds will be used to assess the patient's tolerance to exercise in the absence of the 6MWT ⁴⁰.

195 **Upper limb strength:** will be assessed using hand grip strength measured using a grip strength
196 dynamometer to evaluate functional aspects of muscle strength, and to predict nutritional and general
197 health status of patients^{41,42}.

198 **Blood pressure and resting heart rate:** will be measured using an automated digital
199 sphygmomanometer according to the American Heart Association guidance, using the mean of two
200 measured values⁴³.

201 **Anthropometric proxies of nutritional status:** body measures collected from patients will include
202 body mass (kg), height (m), waist, and hip girth (cm), using International Society for the Advancement
203 of Kinanthropometry (ISAK) procedures⁴⁴. Body mass index (BMI) will be calculated as mass/height²;
204 waist-to-hip ratio (WHR) will be calculated as waist girth/hip girth.

205 **Nutritional status:** will be assessed using the modified Patient-Generated Subjective Global
206 Assessment (mPG-SGA) questionnaire. The mPG-SGA is a validated nutritional assessment tool for
207 cancer patients, which has been found to be easier to use than the original PG-SGA questionnaire and
208 appears to have better predictive validity for survival⁴⁵.

209 **Anxiety:** will be assessed using the Generalised Anxiety Disorder questionnaires (GAD-7)⁴⁶.

210 **Depression:** will be assessed using the Patient Health Questionnaire (PHQ-9)⁴⁷.

211 **Fatigue:** the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) will be used to
212 assess self-reported fatigue levels of patients and its impact upon their daily activities and function⁴⁸.

213 **Self-efficacy:** will be measured using the Self-Efficacy for Exercise Scale (SEE)⁴⁹.

214 **Physical activity:** will be estimated using the exercise vital signs (EVS) tool, which is a valid proxy
215 measure of the total minutes of physical activity patients perform each week⁵⁰.

216 **Hospital data: hospital length of stay (LoS)** will be measured as the total number of days an in-patient
217 remains in hospital during a single admission event and is one of the major indicators for the
218 consumption of hospital resources⁵¹. For the purposes of this evaluation, the number of standard ward

219 bed days as well as critical care bed days required for more advanced support and close monitoring,
220 that patients require during their admission for surgery will be assessed. **Number of emergency**
221 **department readmissions** will be assessed within 30 or 90 days of discharge. These outcomes are
222 commonly used as a measure of patient outcomes following surgery, with increased numbers of
223 readmissions contributing to higher costs to the health system. **One-year survival** following the end
224 of treatment will be used as a clinical endpoint measure to determine the impact of the service on
225 mortality.

226

227 **Process evaluation design**

228 The primary aim of the process evaluation is to understand what aspects of the service did or did not
229 work and why, as well as contribute to the interpretation of the findings of the outcome evaluation.

230 The design of the process evaluation is informed by the Medical Research Council (MRC) guidance on
231 the process evaluation of complex interventions³². The MRC identify three essential features to
232 understand the processes through which outcomes are achieved: context, implementation and
233 mechanisms of impact. The application of this framework is described below, with the relationships
234 between these functions of process evaluation shown in Figure 3.

235

FIGURE 3 HERE

236 The objectives of the process evaluation are to:

- 237 • Assess the reach and dose of the Active Together service delivery.
- 238 • Assess the treatment fidelity of the Active Together service to understand if the service was
239 delivered as intended and whether any adaptations were made.
- 240 • Explore the experience of the Active Together service from the perspective of different
241 stakeholders.

- 242 • Explore the presence of any theoretical mediators that explain changes in patient outcomes
243 and clinical endpoints.

244

245 ***Reach and dose***

246 Service performance indicators will be collected as part of the process evaluation to enable
247 assessment of the reach and dose of the Active Together service. Performance indicators will include
248 referral rates, uptake and adherence to the programme (number of sessions offered versus number
249 of sessions attended), attrition rates of patients leaving the service early, signposting to other services
250 and any documented adverse events. This information described in table 2 will be routinely collected
251 and tracked by the service delivery team. In a subsample of Active Together patients, heart rate and
252 rate of perceived exertion data will be captured to assess the intensity of the exercise being
253 performed.

254

TABLE 2 HERE

255

256 ***Treatment fidelity***

257 Treatment fidelity strategies will be assessed using adapted checklists created by the National Institute
258 for Health-Behaviour Change Consortium (NIH-BCC)⁵², and expanded further by Borelli⁵³. The
259 processes used in the Active Together service will be adapted to balance the realities of assessing
260 treatment fidelity in the 'real world', as opposed to a controlled study environment. Table 3 provides
261 definitions for each of the treatment fidelity components for this evaluation. Treatment fidelity will
262 be assessed for each of the components described within the table (design, training and delivery).

263

TABLE 3 HERE

264 ***Perspectives of stakeholders***

265 Semi-structured interviews and focus groups (face-to-face, telephone or Microsoft Teams) will explore
266 the experiences of the Active Together service from different perspectives, including patients and
267 professionals. We will recruit a diverse range of patients based on ethnicity, socioeconomic group,
268 cancer diagnosis, age, outcomes and engagement with Active Together. Patients will be contacted
269 once they have reached the end of the rehabilitation pathway, so they have experience of the whole
270 service. Healthcare professionals across a range of clinical backgrounds and cancers as well as a range
271 of staff delivering the service will be approached by the evaluation team to take part in an interview
272 at various times during the evaluation. Patients and healthcare professionals will only take part in one
273 interview. The researcher conducting the interviews will follow a pre-defined semi structured
274 interview schedule to minimise potential bias (see supplementary materials). Interview topics for
275 professionals will cover questions on opinions of the service, anticipated impact of Active Together,
276 mechanisms for success and sustainability of the service. Interview topics for patients will cover
277 service expectations, feedback and impact of the service. The data collected during the
278 interviews/focus groups will also be used to capture emerging changes in the implementation of the
279 service, as well as unanticipated or complex causal pathways which could inform new programme
280 theory.

281 Qualitative samples will be large enough to ensure that most, or all the perceptions that might be
282 important within the Active Together aims are uncovered, without being too large to reduce data,
283 becoming repetitive and eventually superfluous.

284 ***Programme theory***

285 The MRC guidance states that underpinning programme theory should be put in place to explain how
286 a project or programme is understood to contribute to a chain of results that produce the intended or
287 actual impact³². This includes seeing service development as a dynamic and iterative process which
288 involves the input from key stakeholders using repeated cycles of development. Those responsible for
289 the design, delivery and evaluation of the Active Together service, have developed programme theory

290 to describe ‘the how’ and ‘the why’ of the Active Together service (Table 4). This is based on learning
291 from other complex system programmes and cancer rehabilitation services. This programme theory
292 describes how the Active Together service is intended to deliver its outcomes and the conditions
293 required to succeed. The programme theory also sets out the causal pathway between the context of
294 the service, intermediate outcomes, and long-term goals and how these interact with contextual
295 factors.

296 **TABLE 4 HERE**

297 Cancer rehabilitation programmes, such as Active Together, are complex in nature due to the
298 interaction of multi-organisation and multi-level components, which could create some barriers to
299 achieving the intended outcomes. During the Active Together programme theory development, logic
300 models were used to communicate various parts of the programme theory (e.g., mechanisms by which
301 the service will achieve its outcomes). Figure 4 is an example of the initial logic model, which will be
302 tested and refined as the service is being delivered. Focus groups with the core Active Together
303 delivery team will be carried out to explore how the service is progressing in relation to the initial logic
304 model, which will help demonstrate theory of change. Topics within the focus group will include
305 questions relating to the team vision, reviewing what is still applicable from the initial logic model and
306 what has changed, barriers to delivery and anticipated delivery plans. Focus groups will take place on
307 three occasions, every six-months. The programme theory and logic models will be refined and
308 amended to reflect any changes.

309 **FIGURE 4 HERE**

310 ***Service refinement and monitoring***

311 The Active Together team will closely monitor and detect significant deviations from the Active
312 Together protocol²⁹, to prevent any issues from being widespread, and long-lasting. The framework
313 recommended by the NIH-BCC will be embedded into the service from the outset to assess if the
314 service is being delivered as intended⁵⁵.

315 As part of continuous service improvement, it is anticipated that Active Together will need to be
316 refined and adapted, either based on data collected or the evolution of the programme theory. By
317 engaging service users and other key stakeholders in service feedback loops, the feasibility and
318 acceptability of the Active Together service will be improved iteratively over time. This refinement
319 process will be a key feature of the Active Together service, ensuring that the service remains patient-
320 focused and evidence based. Any time a significant change is made to the Active Together service
321 delivery or evaluation protocol it will be documented, including the date of the change, exactly which
322 elements of the service or evaluation have changed and the reason for the change. Any changes to
323 the service design and delivery will be reported in subsequent reports and publications where relevant
324 and evaluation data will be analysed and interpreted in light of any alterations.

325

326 **Data analysis**

327 ***Outcome evaluation analysis***

328 Descriptive statistics will summarise the characteristics of patients that access the Active Together
329 service and will be used to assess the diversity of patients from a socio-economic and ethnicity
330 perspective. A one-way repeated measures (within-group) analysis of variance (ANOVA) will be used
331 to determine both the statistical significance of changes in the mean value of patient outcome
332 measures throughout the Active Together pathway and their clinical significance based on pre-defined
333 thresholds where available. This analysis will be performed with all patients considered as a single
334 group and within groups of patients stratified according to demographic characteristics and cancer
335 tumour type, for example. In addition, a between-group ANOVA will enable comparative analysis of
336 changes in these outcome measures throughout the service pathway between these patient sub-
337 groups. Group-based trajectory modelling⁵⁶ will also be used to assess and visualise observed changes
338 in patient outcome measures throughout the Active Together service. Predefined criteria will be
339 applied to ensure patients are eligible for inclusion in the analysis, or how patients are divided into

340 sub-groups. For example, if patients have had a prehabilitation phase (time between initial assessment
341 and start of treatment) lasting less than two weeks, they will be analysed separately from patients
342 that received prehabilitation over a longer period. This is because a previous prehabilitation evidence
343 and insight review recommended that two weeks is the minimum period within which it is feasible to
344 intervene before acute treatment⁵⁷.

345 Economic evaluation of the Active Together service will centre on the value-based healthcare
346 approach, including patient treatment outcomes and the impact on resources. Individual healthcare
347 usage will be obtained retrospectively, thereby restricting the cost analysis to direct healthcare costs.
348 Individual usage will then be scaled up to determine average and unit costs, based on the National
349 Cost Collection Index 2019/20⁵⁸ and from Unit costs of Health and Social Care database⁵⁹. A proxy
350 measure of bed-day cost will be calculated as an average of the excess bed-day tariff for procedures
351 carried out on patients. Critical care tariffs will be used for surgical patients to assess the impacts on
352 critical care. To consider the impact of emergency readmission, a one-day excess bed day tariff will be
353 used. It must be noted that this will not equate to actual cash releasing 'cost savings' but reflects
354 impact on provider costs in terms of bed days and capacity. If this shows a positive outcome, it can be
355 assumed that resources will be redirected and a net efficiency saving for the health system can be
356 demonstrated.

357 ***Process evaluation analysis***

358 Initially, analysis of quantitative process data will include descriptive statistics relating to questions
359 such as fidelity, dose, and reach. Subsequently, quantitative process measures will be integrated with
360 outcomes data to help understand how, for example, implementation variability of the service affects
361 outcomes and theories arising from patient interview responses. By using qualitative data, it could be
362 that patient motivation is supported by other mechanisms, such as social support from other patients.
363 The integration of quantitative measures of psychological change mechanisms with outcome data may
364 help to clarify complex causal pathways within the service. By doing so, it will be possible to

365 understand how the Active Together service works by testing theoretical mediators through which the
366 service exerts its effects to determine whether the Active Together service leads directly to changes
367 in measured patient outcomes, or whether the service changes some intermediary variable, such as
368 self-efficacy, which in turn leads to changes in these outcomes. This combination of data from the
369 quantitative outcome evaluation and the qualitative interview data from the process evaluation
370 within a mixed-methods analysis will enable the findings of the two aspects of the evaluation to be
371 linked together.

372 Verbatim transcription of interview and focus group recordings will be conducted by an external
373 transcription company. These data will be examined using thematic analysis. The approach involves
374 the development of an initial coding index based on the interview guide. The coding index will be
375 implemented to organise the data into themes. The research team will thematically analyse the data⁶⁰
376 and identify key themes raised by patients and professionals regarding the Active Together service. At
377 least one other experienced qualitative researcher will support the analysis to facilitate triangulation
378 and rigour, exploring different interpretations of the data and minimising researcher bias. Each stage
379 of analysis will build an increasingly nuanced understanding of important themes. Data analysis from
380 all stages of the evaluation will be synthesised to form a 3D intervention logic model⁶¹. This model will
381 outline a hypothesised theory of change⁶². This will inform subsequent recommendations for the
382 future development of Active Together.

383 **DISCUSSION**

384 There is increasing evidence supporting the efficacy of rehabilitation (including prehabilitation) as an
385 adjunct to cancer treatment^{22,63-65}. While prospective trials comparing prehabilitation with standard
386 care might yield evidence of comparative treatment effects in experimental measures, evaluation of
387 large cohorts from real-world rehabilitation services can help understand wider clinical value. The
388 evaluation of the Greater Manchester Prehab4Cancer service provides real-world evidence of the
389 effectiveness of cancer prehabilitation for patients, providers and the wider healthcare system⁶⁶. The

390 independent evaluation found there was a reduced demand on healthcare services throughout the
391 cancer pathway, patients benefitted from health improvements prior to surgery and longer-term
392 following post-operative rehabilitation, reduced ward and critical care bed days, and evidence of
393 improved one year survival in colorectal and upper GI cancer patients. When considering the long-
394 term commissioning and sustainability of rehabilitation services, the report concluded that bed days
395 'released' per Prehab4Cancer patient covered the cost of setting up and delivering the service for a
396 year.

397 Despite the increasing scientific evidence of the benefits of cancer rehabilitation, the translation of
398 evidence into practice is less advanced. Cancer rehabilitation is not currently routinely provided as
399 part of standard NHS care. The Active Together service aims to test a model of multimodal
400 rehabilitation embedded within existing cancer care pathways to address the gap in patient care.
401 Findings from the evaluation of Active Together will contribute to the emerging evidence base of the
402 real-world effectiveness of cancer rehabilitation and potentially strengthen the case for widespread
403 uptake and adoption of rehabilitation for cancer patients. The results of this evaluation will provide
404 valuable insight into service implementation and an understanding of impacts on both patient
405 outcomes and the health economic landscape.

406

407

408 **Acknowledgements**

409 Not applicable.

410 For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY)

411 licence to any Author Accepted Manuscript version arising from this submission.

412 **Funding source**

413 The Active Together service is funded by Yorkshire Cancer Research Charity, UK.

414 **Trial registration:** This service evaluation was registered with the Clinical Effectiveness Unit at
415 Sheffield Teaching Hospitals (Reference number 11115).

416 **Ethics approval and consent to participate**

417 All data collection methods and procedures detailed in this protocol will be carried out in accordance
418 with the principles laid out in the Declaration of Helsinki. All procedures detailed in this service
419 evaluation protocol have been reviewed by the Health Research Authority (HRA) who concluded that
420 formal NHS ethical approval was not required because no new or untested treatment is being
421 offered and there is no experimentation being conducted with patients. The service evaluation has
422 been approved by the Clinical Effectiveness Unit (CEU) at Sheffield Teaching Hospitals NHS
423 Foundation Trust (Ref 11115 - 19/5/2022). Informed consent for anonymised data to be used in the
424 service evaluation is obtained from all patients prior to attending or during their initial assessment
425 and data will be processed in accordance with GDPR.

426 **Availability of data and materials**

427 Not applicable. No datasets were generated or analysed for the purposes of this manuscript.

428 **Competing interests**

429 The authors declare that they have no competing interests.

430 **Authors' contributions**

431 AM, GF, CK, KP, GP and MT drafted the manuscript. AM, LH, GF and RC, with support from the Active
432 Together clinical advisory group, designed the project. All authors read and approved the final
433 manuscript for submission.

434 **LIST OF ABBREVIATIONS**

- 435 • **UK:** United Kingdom
- 436 • **LOS:** Length of stay
- 437 • **WHO:** World Health Organisation
- 438 • **AWRC:** Advanced Wellbeing Research Centre
- 439 • **SHU:** Sheffield Hallam University
- 440 • **YCR:** Yorkshire Cancer Research
- 441 • **STH:** Sheffield Teaching Hospitals NHS Foundation Trust

- 442 • **NHS:** National Health Service
- 443 • **6MWT:** 6-minute walk test
- 444 • **SEE:** Self-efficacy for exercise scale
- 445 • **EVS:** Exercise vital signs
- 446 • **mPG-SGA:** Modified patient-generated subjective global assessment
- 447 • **BMI:** Body mass index
- 448 • **SACT:** systemic anti-cancer therapy
- 449 • **CNS:** Clinical Nurse Specialist
- 450 • **HRA:** Health Research Authority
- 451 • **CEU:** Clinical Effectiveness Unit
- 452 • **EOT:** End of treatment
- 453 • **SES:** Socio-economic status
- 454 • **IMD:** Index of Multiple Deprivation
- 455 • **PAR-Q:** Physical Activity Readiness Questionnaire
- 456 • **FACIT-Fatigue:** Functional Assessment of Chronic Illness Therapy-Fatigue
- 457 • **PHQ:** Patient Health Questionnaire
- 458 • **GAD:** Generalised Anxiety Disorder
- 459 • **WHR:** Waist-to-hip ratio
- 460 • **ISAK:** International Society for the Advancement of Kinanthropometry
- 461 • **MRC:** Medical Research Council
- 462 • **NIH-BCC:** National Institute for Health-Behaviour Change Consortium
- 463 • **ANOVA:** Analysis of variance

464
465 **REFERENCES**

- 466 1. Macmillan Cancer Support. Statistics fact sheet the number of people living with cancer.
467 https://www.macmillan.org.uk/_images/cancer-statistics-factsheet_tcm9-260514.pdf. Accessed
468 November, 2022.

- 469 2. Ismail H, Cormie P, Burbury K, Waterland J, Denehy L, Riedel B. Prehabilitation prior to major
470 cancer surgery: Training for surgery to optimize physiologic reserve to reduce postoperative
471 complications. *Curr Anesthesiol Rep*. 2018;8(4):375-385. doi: 10.1007/s40140-018-0300-7.
- 472 3. Pearse RM, Moreno RP, Bauer P, et al. Mortality after surgery in europe: A 7 day cohort study. *The*
473 *Lancet*. 2012;380(9847):1059-1065. doi: 10.1016/S0140-6736(12)61148-9.
- 474 4. Durrand J, Singh SJ, Danjoux G. Prehabilitation. *Clin Med*. 2017;19(6):458. doi:
475 10.7861/clinmed.2019-0257.
- 476 5. Patel N, Powell AG, Wheat JR, et al. Cardiopulmonary fitness predicts postoperative major
477 morbidity after esophagectomy for patients with cancer. *Physiol Rep*. 2019;7(14). doi:
478 10.14814/phy2.14174.
- 479 6. Helander EM, Webb MP, Menard B, et al. Metabolic and the surgical stress response
480 considerations to improve postoperative recovery. *Curr Pain Headache Rep*. 2019;23(5):33. doi:
481 10.1007/s11916-019-0770-4.
- 482 7. Burden ST, Bibby N, Donald K, et al. Nutritional screening in a cancer prehabilitation programme:
483 A cohort study. *Journal of human nutrition and dietetics*. 2022. doi: 10.1111/jhn.13057.
- 484 8. Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of
485 cancer. *Cancer*. 2008;112(S11):2577-2592. doi: 10.1002/cncr.23448.
- 486 9. Macmillan Cancer Support. It's no life. living with the long-term effects of cancer. 2009.
- 487 10. Boele F, Harley C, Pini S, Kenyon L, Daffu-O'Reilly A, Velikova G. Cancer as a chronic illness:
488 Support needs and experiences. *BMJ supportive & palliative care*. 2019;0. doi:
489 10.1136/bmjspcare-2019-001882.
- 490 11. Pituskin E, Fairchild A. Prostate cancer with bone metastases: Addressing chronic pain from the
491 perspective of the radiation oncology nurse practitioner. *Seminars in oncology nursing*.
492 2021;37(4):151175. doi: 10.1016/j.soncn.2021.151175.
- 493 12. Macmillan Cancer Support. Throwing light on the consequences of cancer and its treatment.
494 [https://www.macmillan.org.uk/documents/aboutus/research/researchandevaluationreports/throwi](https://www.macmillan.org.uk/documents/aboutus/research/researchandevaluationreports/throwinglightontheconsequencesofcanceranditstreatment.pdf)
495 [nglightontheconsequencesofcanceranditstreatment.pdf](https://www.macmillan.org.uk/documents/aboutus/research/researchandevaluationreports/throwinglightontheconsequencesofcanceranditstreatment.pdf). Accessed November, 2023.
- 496 13. Armes J, Crowe M, Colbourne L, et al. Patients' supportive care needs beyond the end of cancer
497 treatment: A prospective, longitudinal survey. *Journal of clinical oncology*. 2009;27(36):6172-6179.
498 doi: 10.1200/JCO.2009.22.5151.
- 499 14. Mann J, Kerr K. The impact of major surgery in the unfit and deprived. *Anaesthesia*.
500 2021;76(S2):16-165. doi: 10.1111/anae.15338.
- 501 15. Lai-Kwon J, Jefford M. Improving care for cancer survivors. *Expert Review of Quality of Life in*
502 *Cancer Care*. 2017;2(5):251. doi: 10.1080/23809000.2017.1378072.
- 503 16. Grimmer C, Heneka N, Chambers S. Psychological interventions prior to cancer surgery: A review
504 of reviews. *Curr Anesthesiol Rep*. 2022;12(1):78-87. doi: 10.1007/s40140-021-00505-x.
- 505 17. Macmillan Cancer Support. The importance of physical activity for people living with and beyond
506 cancer: A concise evidence review . https://www.macmillan.org.uk/_images/the-importance-

- 507 physical-activity-for-people-living-with-and-beyond-cancer_tcm9-290123.pdf. Accessed November,
508 2023.
- 509 18. West M, Bates A, Grimmett C, et al. The wessex fit-4-cancer surgery trial (WesFit): A protocol for
510 a factorial-design, pragmatic randomised-controlled trial investigating the effects of a multi-modal
511 prehabilitation programme in patients undergoing elective major intra-cavity cancer surgery.
512 *F1000Res.* 2021;10. doi: 10.12688/f1000research.55324.2.
- 513 19. Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J. A systematic review of exercise
514 systematic reviews in the cancer literature (2005-2017). *PM&R.* 2017;9(9S2):S347-S384. doi:
515 10.1016/j.pmrj.2017.07.074.
- 516 20. Bradley P, Merchant Z, Rowlinson-Groves K, Taylor M, Moore J, Evison M. Feasibility and
517 outcomes of a real-world regional lung cancer prehabilitation programme in the UK. *British journal*
518 *of anaesthesia : BJA.* 2022. doi: 10.1016/j.bja.2022.05.034.
- 519 21. Lukez A, Baima J. The role and scope of prehabilitation in cancer care. *Seminars in oncology*
520 *nursing.* 2020;36(1):150976. doi: 10.1016/j.soncn.2019.150976.
- 521 22. Waterland JL, Mccourt O, Edbrooke L, et al. Efficacy of prehabilitation including exercise on
522 postoperative outcomes following abdominal cancer surgery: A systematic review and meta-
523 analysis. *Front Surg.* 2021;8. doi: 10.3389/fsurg.2021.628848.
- 524 23. Cormie P, Zopf EM, Zhang X, Schmitz KH. The impact of exercise on cancer mortality, recurrence,
525 and treatment-related adverse effects. *Epidemiologic reviews.* 2017;39(1):71-92. doi:
526 10.1093/epirev/mxx007.
- 527 24. Brown JC, Gilmore LA. Physical activity reduces the risk of recurrence and mortality in cancer
528 patients. *Exercise and sport sciences reviews.* 2020;48(2):67-73. doi:
529 10.1249/JES.0000000000000214.
- 530 25. Schwedhelm C, Boeing H, Hoffmann G, Aleksandrova K, Schwingshackl L. Effect of diet on
531 mortality and cancer recurrence among cancer survivors: A systematic review and meta-analysis of
532 cohort studies. *Nutr Rev.* 2016;74(12).
- 533 26. Basen-engquist K, Alfano CM, Maitin-shepard M, et al. Agenda for translating physical activity,
534 nutrition, and weight management interventions for cancer survivors into clinical and community
535 practice. *Obesity.* 2017;25(S2):9. doi: 10.1002/oby.22031.
- 536 27. McTiernan A, Friedenreich CM, Katzmarzyk PT, et al. Physical activity in cancer prevention and
537 survival: A systematic review. *Med Sci Sports Exerc.* 2019;51(6):1252-1261. doi:
538 10.1249/MSS.0000000000001937.
- 539 28. Patel AV, Friedenreich CM, Moore SC, et al. American college of sports medicine roundtable
540 report on physical activity, sedentary behavior, and cancer prevention and control. *Medicine &*
541 *Science in Sports & Exercise.* 2019;51(11). doi: 10.1249/MSS.0000000000002117.
- 542 29. Humphreys L, Myers A, Frith G, et al. The development of a multi-modal cancer rehabilitation
543 (including prehabilitation) service in sheffield, UK: Designing the active together service. *Healthcare.*
544 (Under Review).
- 545 30. Keen C, Phillips G, Thelwell M, Humphreys L, Evans L, Copeland R. Establishing innovative
546 complex services: Learning from the active together cancer prehabilitation and rehabilitation
547 service. *Healthcare.* 2023;11(23). doi: 10.3390/healthcare11233007.

- 548 31. Des Jarlais DC, Lyles C, Crepaz N. Improving the reporting quality of nonrandomized evaluations
549 of behavioral and public health interventions: The TREND statement. *American journal of public*
550 *health* (1971). 2004;94(9):1474-1475. doi: 10.2105/AJPH.94.9.1474-a.
- 551 32. Skivington K, Matthews L, Simpson SA, et al. A new framework for developing and evaluating
552 complex interventions: Update of medical research council guidance. *BMJ*. 2021. doi:
553 10.1136/bmj.n2061.
- 554 33. Schmidt K, Vogt L, Thiel C, Jäger E, Banzer W. Validity of the six-minute walk test in cancer
555 patients. *International journal of sports medicine*. 2013;34(7):631-636. doi: 10.1055/s-0032-
556 1323746.
- 557 34. Marjanski T, Badocha M, Wnuk D, et al. Result of the 6-min walk test is an independent
558 prognostic factor of surgically treated non-small-cell lung cancer. *Interact CardioVasc Thorac Surg*.
559 2019;28(3):368-374. doi: 10.1093/icvts/ivy258.
- 560 35. Awdeh H, Kassak K, Sfeir P, Hatoum H, Bitar H, Husari A. The SF-36 and 6-minute walk test are
561 significant predictors of complications after major surgery. *World J Surg*. 2015;39(6):1406-1412. doi:
562 10.1007/s00268-015-2961-4.
- 563 36. Ezzatvar Y, Ramírez-Vélez R, Sáez de Asteasu M,L., et al. Physical function and all-cause mortality
564 in older adults diagnosed with cancer: A systematic review and meta-analysis. *J Gerontol A Biol Sci*
565 *Med Sci*. 2021;76(8):1447-1453. doi: 10.1093/gerona/glaa305.
- 566 37. Verweij NM, Schiphorst AHW, Pronk A, van den Bos F, Hamaker ME. Physical performance
567 measures for predicting outcome in cancer patients: A systematic review. *Acta Oncol*.
568 2016;55(12):1386-1391. doi: 10.1080/0284186X.2016.1219047.
- 569 38. Rabin R, Charro Fd. EQ-SD: A measure of health status from the EuroQol group. *Annals of*
570 *medicine* (Helsinki). 2001;33(5):337-343. doi: 10.3109/07853890109002087.
- 571 39. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in
572 community-residing older adults. *Research quarterly for exercise and sport*. 1999;70(2):113-119. doi:
573 10.1080/02701367.1999.10608028.
- 574 40. Gofus J, Vobornik M, Koblizek V, Pojar M, Vojacek J. The outcome of a preoperative one-minute
575 sit-to-stand test is associated with ventilation time after cardiac surgery. *Scandinavian cardiovascular*
576 *journal : SCJ*. 2021;55(3):187-193. doi: 10.1080/14017431.2020.1866771.
- 577 41. Norman K, Stobäus N, Gonzalez MC, Schulzke J, Pirlich M. Hand grip strength: Outcome predictor
578 and marker of nutritional status. *Clinical Nutrition*. 2011;30(2):135-142. doi:
579 10.1016/j.clnu.2010.09.010.
- 580 42. Valente KP, Almeida BL, Lazzarini TR, et al. Association of adductor pollicis muscle thickness and
581 handgrip strength with nutritional status in cancer patients. *PLoS One*. 2019;14(8):e0220334. doi:
582 10.1371/journal.pone.0220334.
- 583 43. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in
584 humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for
585 professionals from the subcommittee of professional and public education of the american heart
586 association council on high blood pressure research. *Circulation*. 2005;111(5):697-161. doi:
587 10.1161/01.CIR.0000154900.76284.F6.

- 588 44. Stewart A, Marfell-Jones M, Olds T, De Ridder H. International standards for anthropometric
589 assessment. Third Edition ed. New Zealand: International Society for the Advancement of
590 Kinanthropometry; 2011.
- 591 45. Fu Z, Zhang R, Wang K, et al. Development and validation of a modified Patient-Generated
592 subjective global assessment as a nutritional assessment tool in cancer patients. *J cachexia*
593 *sarcopenia muscle*. 2021;13(1).
- 594 46. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety
595 disorder: The GAD-7. *Arch Intern Med*. 2006;166(10):1092-1097. Accessed 3/8/2024. doi:
596 10.1001/archinte.166.10.1092.
- 597 47. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. *J*
598 *Gen Intern Med*. 2001;16(9):606-613. doi: 10.1046/j.1525-1497.2001.016009606.x.
- 599 48. Acaster S, Dickerhoof R, Debusk K, Bernard K, Strauss W, Allen LF. Qualitative and quantitative
600 validation of the FACIT-fatigue scale in iron deficiency anemia. *Health Qual Life Outcomes*.
601 2015;13(1). doi: 10.1186/s12955-015-0257-x.
- 602 49. Resnik B, Jenkins L. Testing the reliability and validity of the self-efficacy for exercise scale.
603 *Nursing Research*. 2000:154-159. doi: 10.1097/00006199-200005000-00007.
- 604 50. Golightly YM, Allen KD, Ambrose KR, et al. Physical activity as a vital sign: A systematic review.
605 *Prev. Chronic Dis*. 2017;14. doi: 10.5888/pcd14.170030.
- 606 51. Stone K, Zwiggelaar R, Jones P, Mac Parthaláin N. A systematic review of the prediction of
607 hospital length of stay: Towards a unified framework. *PLOS digital health*. 2022;1(4):e0000017. doi:
608 10.1371/journal.pdig.0000017.
- 609 52. Bellg A, Borelli B, Resnick B, et al. Enhancing treatment fidelity in health behavior change studies:
610 Best practices and recommendations from the NIH behavior change consortium. *Health Psychology*.
611 2004;23(5):443-451. doi: 10.1037/0278-6133.23.5.443.
- 612 53. Borrelli B. The assessment, monitoring, and enhancement of treatment fidelity in public health
613 clinical trials. *Journal of public health dentistry*. 2011;71(s1):S52-S63. doi: 10.1111/j.1752-
614 7325.2011.00233.x.
- 615 54. Guest G, Bunce A, Johnson L. How many interviews are enough?: An experiment with data
616 saturation and variability. *Field Methods*. 2016;18(1). doi: 10.1177/1525822X0527990.
- 617 55. Ory MG, Jordan PJ, Bazzarre T. The behavior change consortium: Setting the stage for a new
618 century of health behavior-change research. *Health education research*. 2002;17(5):500-511. doi:
619 10.1093/her/17.5.500.
- 620 56. Nagin DS. Group-based trajectory modeling: An overview. *Ann Nutr Metab*. 2014;65(2-3):205.
621 doi: 10.1159/000360229.
- 622 57. Bloom K. Prehabilitation evidence and insight review.
623 [https://www.macmillan.org.uk/_images/prehabilitation-evidence-and-insight-review_tcm9-](https://www.macmillan.org.uk/_images/prehabilitation-evidence-and-insight-review_tcm9-335025.pdf)
624 [335025.pdf](https://www.macmillan.org.uk/_images/prehabilitation-evidence-and-insight-review_tcm9-335025.pdf). Accessed November, 2023.
- 625 58. NHS England. National cost collection for the NHS. [https://www.england.nhs.uk/costing-in-the-](https://www.england.nhs.uk/costing-in-the-nhs/national-cost-collection/2022)
626 [nhs/national-cost-collection/2022](https://www.england.nhs.uk/costing-in-the-nhs/national-cost-collection/2022).

- 627 59. University of Kent. Unit costs of health and social care. <https://www.pssru.ac.uk/project->
628 [pages/unit-costs/2022](https://www.pssru.ac.uk/project-pages/unit-costs/2022).
- 629 60. Braun V, Clarke V. Successful qualitative research: A practical guide for beginners. First Edition
630 ed. United Kingdom: SAGE; 2013.
- 631 61. Fletcher A, Jamal F, Moore G, Evans RE, Murphy S, Bonell C. Realist complex intervention science:
632 Applying realist principles across all phases of the medical research council framework for
633 developing and evaluating complex interventions. *Evaluation* (London, England : 1995).
634 2016;22(3):286-303. doi: 10.1177/1356389016652743.
- 635 62. De Silva MJ, Breuer E, Lee L, et al. Theory of change: A theory-driven approach to enhance the
636 medical research council's framework for complex interventions. *Trials*. 2014;15(1):267. doi:
637 10.1186/1745-6215-15-267.
- 638 63. Coderre D, Brahmhatt P, Hunter TL, Baima J. Cancer prehabilitation in practice: The current
639 evidence. *Curr Oncol Rep*. 2022;24(11):1569-1577. doi: 10.1007/s11912-022-01304-1.
- 640 64. Sleight A, Gerber LH, Marshall TF, et al. Systematic review of functional outcomes in cancer
641 rehabilitation. *Archives of Physical Medicine and Rehabilitation*. 2022;103(9):1807. doi:
642 10.1016/j.apmr.2022.01.142.
- 643 65. Stout NL, Santa Mina D, Lyons KD, Robb K, Silver JK. A systematic review of rehabilitation and
644 exercise recommendations in oncology guidelines. *CA A Cancer J Clin*. ;71(2). doi:
645 10.3322/caac.21639.
- 646 66. Greater Manchester Cancer. Prehab4Cancer evaluation - Greater Manchester Cancer.
647 [https://wessexcanceralliance.nhs.uk/wp-](https://wessexcanceralliance.nhs.uk/wp-content/uploads/2022/01/GM_Prehab4Cancer_Evaluation_Report_Final.pdf)
648 [content/uploads/2022/01/GM_Prehab4Cancer_Evaluation_Report_Final.pdf](https://wessexcanceralliance.nhs.uk/wp-content/uploads/2022/01/GM_Prehab4Cancer_Evaluation_Report_Final.pdf). Accessed October,
649 2021.

TABLES

Table 1. Schedule and details of outcome measures to be collected during Active Together service.

| Patient outcome | Prehabilitation | | The type and duration of treatment will vary between participants | Rehabilitation (Maintenance / Restorative / Supportive) | | | |
|---|-----------------|-------------------|---|---|----------------------|---------------------|------------------------|
| | T1: Pre-prehab | T2: Pre-treatment | | T3: Post-treatment | T4: Post-restorative | T5: Post-supportive | T6: 12-month follow-up |
| Eligibility | ✓ | | | | | | |
| Cancer diagnosis (site, stage, etc.) | ✓ | | | | | | |
| Socio-demographics (age, sex, ethnicity, postcode (IMD)) | ✓ | | | | | | |
| Medical history | ✓ | | | | | | |
| Anthropometry (height, mass (BMI); waist and hip circumference (WHR)) | ✓ | ✓ | | ✓ | ✓ | ✓ | |
| Aerobic capacity (6MWT) | ✓ | ✓ | | ✓ | ✓ | ✓ | |
| Hand grip strength (Dynamometer) | ✓ | ✓ | | ✓ | ✓ | ✓ | |
| Leg strength/endurance (30 and 60s sit-to-stand test) | ✓ | ✓ | | ✓ | ✓ | ✓ | |
| Blood pressure and resting HR (Sphygmomanometer) | ✓ | ✓ | | ✓ | ✓ | ✓ | |
| Physical activity level (EVS) | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ |
| Health-related quality of life (EQ-5D-5L) | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ |
| Fatigue (FACIT-Fatigue) | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ |
| Nutritional state (mPG-SGA) | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ |
| Anxiety and depression (PHQ-9/GAD-7) | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ |
| Self-efficacy (SEE) | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ |
| Electronic patient record | | | | | | | ✓ |

IMD: Index of Multiple Deprivation; BMI: body mass index; WHR: waist-to-hip ratio; 6MWT: six-minute walk test; HR: heart rate; EVS: exercise vital signs; FACIT-Fatigue: Functional Assessment of Chronic Illness Therapy-Fatigue; PHQ: Patient Health Questionnaire; GAD: Generalised Anxiety Disorder; SEE: Self-efficacy for exercise; mPG-SGA: modified patient-generated subjective global assessment.

Table 2. Service performance indicators.

| Outcome | Measurement method |
|---|---------------------------|
| Referral into service | Service delivery records |
| Source of referral | Service delivery records |
| Uptake of the service (conversion ratio) | Service delivery records |
| Reasons for opt-out | Service delivery records |
| Reasons for leaving the service | Service delivery records |
| Attendance levels | Service delivery records |
| Attrition rates | Service delivery records |
| Stage of treatment (prehab, maintenance, rehab) | Service delivery records |
| Service completion rates | Service delivery records |
| Number of patients referred to support services (e.g., smoking cessation and complementary therapies) | Service delivery records |
| Adverse events associated with the service | Service delivery records |
| Participant satisfaction with the service | Questionnaire |

Table 3. Treatment fidelity: what and how.

| Treatment fidelity component | Definition | How it will be delivered |
|-------------------------------------|---|--|
| Design | The theoretical model and guidelines of the hypothesis that is being tested. It includes factors to consider when designing the study which can help in future to ensure replication. | <ul style="list-style-type: none"> • Documentation will be checked, and key members of the management team will be interviewed about the design of the service. • NIH-BCC checklists will be used to ensure that the design is compliant with the key fidelity components. |
| Training | To ensure that Active Together delivery staff receive adequate training prior to and during service delivery. | <ul style="list-style-type: none"> • Documentation will be checked, and key members of the management and delivery team will be asked about the training they received. • NIH-BCC checklists will be used to ensure that the training is compliant with the key fidelity components. |
| Delivery | To confirm that the Active Together content and quantity of the intervention are delivered as intended and that each session adheres to the intervention protocol. | <ul style="list-style-type: none"> • Delivery staff will be observed delivering sessions to patients. • NIH-BCC checklists will be used to ensure that the delivery is compliant with the key fidelity components. |

Table 4. Active Together programme theory.

| If | Then | Because |
|---|---|---|
| <ul style="list-style-type: none"> • Key professionals (non-clinical and clinical) come together to form an improvement team to address any changes to the service • The Active Together team will engage regularly with patients to gain patient feedback • The Active Together team and healthcare professionals from STH regularly review quality improvement approaches, and • All relevant stakeholders are updated and made aware of the project and improvement goals • Processes are fully transparent between the Active Together team and cancer clinical teams • There is an explicit common purpose or agenda and agreed direction of travel for the Active Together service • Commit to having ongoing dialogue with end users and recognise the need for iteration to find approaches that resonate with patients • There is a sense of trust across the system in what the Active Together team are trying to do (a sense of working for the greater good) | <ul style="list-style-type: none"> • A shared view of performance and service improvement gaps can be created • The Active Together team can work as a team to define and achieve service improvement goals • Basic quality improvement approaches can be employed to achieve the improvement goals • Stakeholders will be more engaged in the need for change and aware of how improvement will occur • Cross sector collaboration is more likely | <ul style="list-style-type: none"> • Improved joined up working can be achieved across the system • Improvements in Active Together service delivery in line with the recommended rehabilitation pathway can be achieved • Patients are most adequately prepared physically and psychologically for their cancer journey • Patient outcomes are improved in the long-term |

FIGURES




Figure 1. Phases of Active Together service pathway and assessment points.




Figure 2. Examples of different treatment pathway scenarios.





Figure 3. Description and relationships between the three dimensions of the process evaluation.

Evaluation protocol of the Active Together service



PT: physical trainer; AWRC: Advance Wellbeing Research Centre; SIV: Sheffield International Venues; STH: Sheffield Teaching Hospitals; YCR: Yorkshire Cancer Research; HCP: healthcare professionals; PA: physical activity; CCG: clinical commissioning group; CNS: clinical nurse specialist; MDT: multidisciplinary team; MCID: minimal clinically important difference.

Figure 4. Initial logic model for the Active Together service in Sheffield.